Merck & Co. (MRK) to Acquire Terns Pharma for $6.7 Billion

What: Merck & Co. (MRK) will acquire Terns Pharma for approximately $6.7 billion.
Why: The acquisition aims to strengthen Merck's oncology pipeline with Terns' innovative cancer therapies.
Signal: This deal marks Merck's largest acquisition in over a decade, highlighting the company's commitment to expanding its presence in the oncology market.
Target: The acquisition is expected to close in the second half of 2026, pending regulatory approvals.
Risk: The integration of Terns' operations may pose challenges, including potential disruptions to Merck's existing business and the need to adapt to new regulatory requirements.